KOSDAQElectrical Equipment208370

SELVAS Healthcare

₩2,035▼ 0.97%2026-11-18 close
Market Cap
₩52.4B
Turnover
₩600M
Volume
270K
Shares out.
25.7M
PER
12.0×
PBR
0.8×
EPS
₩194
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

SELVAS Healthcare: body-composition growth amid losses and an audit sanction

Body-composition analyzers are reshaping the sales mix, yet the company swung to an operating loss in 2025, posted net losses attributable to controlling shareholders in the second and third quarters of 2026, and received a designated-auditor sanction in November 2026.

  1. 1

    Annual sales fell to KRW 30.8 billion in 2025, down 2.8% from the prior year, and the company posted an operating loss of KRW 162 million after an operating profit in 2024. The company attributed the decline to higher R&D spending and bad-debt expenses.

  2. 2

    The second quarter of 2026 recorded a net loss attributable to controlling shareholders of KRW 8.68 billion, and the third quarter swung to an operating loss of KRW 229 million. Third-quarter sales still rose 7.3% year on year to KRW 7.2 billion but did not translate into operating profit.

  3. 3

    On November 11, 2026, the Securities and Futures Commission approved a two-year designated-auditor measure over overstated goodwill and development costs and understated inventory valuation allowances in 2018, with the fine to be set later by the Financial Services Commission.

  4. 4

    Body-composition analyzers are expanding through overseas channels, and the company said about 80% of its sales come from outside Korea.

  5. 5

    Selvas AI and two related parties hold 39.66% of the shares outstanding (as of September 28, 2026).

02

Business structure

SELVAS Healthcare is an affiliate of Selvas AI that develops medical devices such as body-composition analyzers and blood pressure monitors, along with assistive devices for the visually impaired.

Based on a DART sales breakdown for 2025, body-composition analyzers generated about KRW 9.59 billion (roughly 31% of sales), braille information terminals about KRW 9.55 billion, and blood pressure monitors about KRW 3.88 billion.

Seoul Economic Daily reported that body-composition analyzers reached about 60% of sales, while the same breakdown implies roughly 39% for the first half of 2026, so the two figures appear to use different bases.

The company said body-composition analyzer sales grew 150% in 2025, but the same table shows about KRW 12.6 billion in 2024, which suggests the measurement basis differs.

Overseas distribution centers on a cooperation with Australian body-composition company Evolt, whose EVOLT 360 is installed at roughly 6,500 units in 51 countries. The company said about 80% of sales come from overseas.

On the assistive side, the Hansone braille terminal is credited with gaining domestic share and entering the U.S. market, which helped return the segment to operating profit. Key segments are the Accunix diagnostic device line and assistive devices for the visually impaired.

Although the sector classification is electrical equipment, the business is medical devices and assistive devices, which limits direct comparison with listed peers. At group level, the company builds a healthcare ecosystem with Selvas AI and Medians.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩6.7B₩500M8.1%
2025Q4₩10.2B-₩21,896,902−0.2%
2026Q1₩6.6B₩700M10.2%
2026Q2₩8.2B₩400M4.5%
2026Q3₩7.2B-₩200M−3.2%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩27.7B₩2.3B₩2.7B8.4%8.1%37.1%
2023₩29.8B₩3.3B₩5.2B11.2%8.6%11.0%
2024₩31.7B₩3.3B₩3.2B10.3%4.9%10.1%
2025₩30.8B-₩200M₩3.9B−0.5%5.5%11.1%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-13

04

Earnings analysis

Annual sales rose from KRW 27.7 billion in 2022 to KRW 29.8 billion in 2023 (up 7.7%) and KRW 31.7 billion in 2024 (up 6.3%), then fell to KRW 30.8 billion in 2025 (down 2.8%). Among 2022 to 2025, 2024 was the largest year for sales.

Operating profit grew from KRW 2.32 billion in 2022 to KRW 3.35 billion in 2023 (up 44.3%), eased to KRW 3.27 billion in 2024 (down 2.2%), and turned into an operating loss of KRW 162 million in 2025. Operating margin was 8.4% in 2022, 11.2% in 2023, 10.3% in 2024, and -0.5% in 2025.

The company attributed the 2025 decline in operating profit to higher costs from new R&D investment and bad-debt expenses, while improved non-operating items lifted pre-tax income.

Net income attributable to controlling shareholders reached KRW 5.17 billion in 2023 (up 95.1%), the largest year in the period, fell to KRW 3.15 billion in 2024 (down 39.0%), and rose to KRW 3.89 billion in 2025 (up 23.4%).

Operating cash flow went from KRW 50.81 million in 2022 to KRW 3.47 billion in 2023 and KRW 4.5 billion in 2024, then dropped to KRW 305 million in 2025.

The debt ratio stayed low at 11.0% in 2023, 10.1% in 2024, and 11.1% in 2025, with total equity of KRW 71.1 billion and total liabilities of KRW 7.86 billion at the end of 2025.

Quarterly sales were KRW 6.71 billion in the third quarter of 2025, KRW 10.2 billion in the fourth quarter (up 52.0% from the prior quarter), KRW 6.58 billion in the first quarter of 2026 (down 35.4%), KRW 8.2 billion in the second quarter (up 24.6%), and KRW 7.2 billion in the third quarter of 2026 (down 12.2%).

Operating profit swung from a loss of KRW 21.9 million in the fourth quarter of 2025 to KRW 669 million in the first quarter of 2026, fell to KRW 372 million in the second quarter (down 44.3%), and turned into an operating loss of KRW 229 million in the third quarter.

Net income attributable to controlling shareholders reached KRW 13.2 billion in the first quarter of 2026, well above operating profit, and an aggregator's breakdown shows pre-tax income excluding special items was far lower, so non-operating items drove the quarterly swing.

Net losses attributable to controlling shareholders were KRW 8.68 billion in the second quarter and KRW 3.18 billion in the third quarter of 2026, making two consecutive loss quarters. The sum of the last four quarters' net income attributable to controlling shareholders is KRW 5.01 billion. An industry summary reported that the first half of 2026 returned to operating and net profit.

05

Industry analysis

Market research cited by Kiwoom-style company monitor data expects medical device growth from population aging and the spread of digital healthcare. The same source projects double-digit annual growth for assistive devices, supported by expanding welfare policy and AI and ICT adoption.

Body-composition analyzers target both hospital demand and fitness and wellness demand. At KIMES 2026, the company unveiled an EMR interface and an AI echocardiography guidance solution for hospitals, along with the BC2000 for fitness use.

Its AI feature combines body-composition data with health screening data to predict disease risk. Overseas, expanding U.S. fitness through the Australian partner is the main route. Assistive devices gain from domestic share and U.S. entry, but their growth depends on welfare-policy expansion, so budget changes matter.

Share versus rival analyzers cannot be measured reliably from the data available here. The parent Selvas AI runs AI healthcare as a separate listed company, and the group ecosystem is presented as the base for expansion.

Because the sector classification is electrical equipment, a direct comparison with sector financial metrics can distort interpretation.

06

Outlook

At KIMES 2026, the company said it aimed to expand total sales by more than 35% in 2026 from the prior year. However, first-half 2026 sales rose only 6.2% year on year, and third-quarter 2026 sales rose just 7.3%, so the gap between target and results is the next checkpoint.

The BC2000 was reported as targeting a launch in the third quarter of 2026, and whether it launched and how much it contributes should be checked in product-level sales in later periodic reports.

New devices, including a stroke diagnostic guidance device, are in preparation, and the company plans to combine Selvas AI's AI technology and cloud systems. A second ARPA-H project worth KRW 12.7 billion was reported in 2025.

The two-year designated-auditor measure changes the external audit framework, and the Financial Services Commission will finally decide the fine amount later. The 2026 annual report will show whether operating margin and sales growth are closing the gap with the company's target.

07

Valuation

PER
12.0×
PBR
0.8×
ROE
7.3%
EPS
₩194
BPS
₩2,804
Dividend per share
₩0

Because operating profit turned to a loss in 2025, multiples based on operating profit are hard to interpret, and the weight shifts to net income and asset-based measures.

The sum of the last four quarters' net income attributable to controlling shareholders is KRW 5.01 billion, a small base, so earnings-based multiples move sharply with quarterly swings.

Excluding 2022, the year-end PER in past data was generally above 20 times, and the current multiple sits near the lower end of that historical range. PBR was below every year-end observation from 2020 to 2024, which places the market valuation of net assets lower than in the past.

The discount reflects the 2025 loss, the quarterly losses in 2026, and the audit sanction together. Operating cash flow fell to KRW 305 million in 2025 from KRW 4.5 billion in 2024, so the link between earnings and cash generation is a point to check. With a large equity base, asset-based comparisons carry more weight.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-13

08

Bull factors

Overseas fitness channel expansion

Body-composition analyzers are widening distribution in the U.S. fitness market through the Australian partner Evolt. The company said EVOLT 360 is installed at about 6,500 units in 51 countries and sits in roughly 2,800 outlets of a large fitness chain. The company said about 80% of sales come from overseas. The company also claims body-composition analyzer sales grew 150% in 2025.

Room for margin recovery

Operating margin was 11.2% in 2023 and 10.3% in 2024, then fell to -0.5% in 2025. The disclosure attributed the 2025 drop mainly to higher R&D costs and bad-debt expenses. The bullish argument is that stabilizing these costs could bring margins back toward the double-digit levels of the past. An aggregator reported that operating profit returned to positive in the first half of 2026.

AI-linked product pipeline

The BC2000 is a fitness body-composition analyzer that was reported as targeting a launch in the third quarter of 2026. An AI module combines body-composition data with five years of health screening data to estimate individual disease risk, which the company presents as a differentiator.

A stroke diagnostic guidance device and the integration of Selvas AI's AI and cloud technology are also in preparation.

09

Bear factors

Designated auditor and fine uncertainty

On November 11, 2026, the Securities and Futures Commission approved a two-year designated-auditor measure against the company.

For 2018, the inquiry found overstated goodwill of KRW 4.85 billion, development costs of KRW 974 million, and investments in subsidiaries of KRW 876 million, along with understated inventory valuation allowances of KRW 3.38 billion on a consolidated basis. The Financial Services Commission will finally decide the fine later.

Continued quarterly losses

Net losses attributable to controlling shareholders were KRW 8.68 billion in the second quarter and KRW 3.18 billion in the third quarter of 2026, two consecutive loss quarters. Third-quarter sales rose 7.3% year on year to KRW 7.2 billion, yet the quarter swung to an operating loss of KRW 229 million.

First-half 2026 sales growth of 6.2% is some distance from the company's target of more than 35% for the full year.

R&D and bad-debt cost burden

Operating profit in 2025 turned to a loss because of higher R&D spending and bad-debt expenses. Operating cash flow fell to KRW 305 million in 2025 from KRW 4.5 billion in 2024.

Net income attributable to controlling shareholders of KRW 13.2 billion in the first quarter of 2026 far exceeded operating profit, so non-operating items played a large role and need careful reading.

10

Risk factors

Accounting and audit risk

The designated-auditor measure changes the external audit framework, and the fine amount has not been set. Because accounting violations were confirmed for an earlier year, the reliability of financial statements becomes a variable in future evaluation. The fine decision and audit opinions will set the premise for interpreting future results.

Earnings volatility

Quarterly sales swung widely, from KRW 10.2 billion in the fourth quarter of 2025 to KRW 6.58 billion in the first quarter of 2026, a 35.4% decline. Because non-operating items move net income sharply, the trend is hard to read from quarterly results alone.

While quarterly losses continue, the trend in cost structure, especially R&D and bad-debt expenses, is the key variable.

Overseas dependence and ownership structure

About 80% of sales come from overseas, exposing the company to exchange rates and changes in partner distribution routes. Selvas AI and two related parties hold 39.66%, so the free float is about 60%. The ownership structure can amplify trading liquidity and price volatility.

11

What to watch next

  1. After November 2026, date not set

    Final fine decision by the Financial Services Commission. Once the amount is set, the financial burden of the sanction can be measured.

  2. Around mid-February 2027

    Disclosure of 2026 annual results, based on the precedent that 2025 annual results were disclosed on February 19, 2026. Annual operating margin and sales growth will show the gap with the company's target.

  3. End of March 2027

    Submission of the 2026 annual report. Product-level sales and consolidated notes will show the body-composition analyzer share and whether the fine is reflected.

  4. Mid-May 2027

    First-quarter 2027 quarterly report. It will show whether operating results recover after the 2026 quarterly losses and whether non-operating items shrink in weight.

  5. Date not set, after November 2026

    Whether the BC2000 has launched and the timing of the stroke diagnostic guidance device. Launch timing and the size of sales contribution need to be confirmed.

12

Overall view

SELVAS Healthcare's sales mix is shifting toward body-composition analyzers, and its widening overseas channels are a growth driver.

Against that, an operating loss in 2025, net losses attributable to controlling shareholders in the second and third quarters of 2026, and the two-year designated-auditor measure approved on November 11, 2026 overlap. Annual sales rose from KRW 27.7 billion in 2022 to KRW 30.8 billion in 2025, though 2025 fell 2.8%.

Operating margin declined from 11.2% in 2023 to -0.5% in 2025, and the company cited higher R&D spending and bad-debt expenses. First-quarter 2026 net income of KRW 13.2 billion far exceeded operating profit, so the weight of non-operating items deserves attention.

The sum of the last four quarters' net income attributable to controlling shareholders is KRW 5.01 billion, and PBR sits below past year-end observations. The gap between the company's target of more than 35% sales growth for 2026 and the 6.2% first-half increase is the next point to check.

The fine amount and timing, along with the operating margin in the 2026 annual report, will serve as the reference points.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. sedaily.com
  2. comp.wisereport.co.kr
  3. news.nate.com
  4. biz.dima.tools
  5. jobkorea.co.kr
  6. investing.com
  7. comp.fnguide.com
  8. news.nate.com
  9. jasoseol.com
  10. google.com
  11. hellot.net
  12. etoday.co.kr
  13. m.ddaily.co.kr
  14. v.daum.net
  15. selvashealthcare.com
  16. newspim.com
  17. m.news.nate.com

Report written 2026-11-14 · Data as of 2026-11-13

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis